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92 Phase III study (IMPACTT) on anti-pseudomonas IgY
A. Larsson1. 1Uppsala University for the IMPACTT Consortium, Uppsala, Sweden
Anti-pseudomonas IgY (Anti-PA IgY), an antibody from hens egg yolk, is specif-
ically designed against Pseudomonas aeruginosa (PA). It is taken as a medication
by gargling and swallowing every night. Earlier studies show that it prolongs time
between infections with PA, postpones start of chronic PA infections and diminishes
the use of antibiotics. Anti-PA IgY is granted Orphan drug designation by EMA.
A multicentre, randomized, double-blind, placebo controlled phase III study will
start 2011 with economic support by EC. The details are now under scrutiny.
Coordinator is Anders Larsson, Uppsala University. Sponsor for the clinical part is
Mucoviszidose Inst., led by Andreas Reimann. CF-centres in the clinical study are
from Germany, Sweden, Denmark, France and Italy; Belgium, Poland and Czech
Republic are standing by. Antje Schuster is principal investigator. The microbiologic
lab, Copenhagen (Niels Ho¨jby), takes care of all microbiologic tests. Hans Kollberg
has compiled the study protocol. Details about it will be given at the conference.
180 CF-patients, who have had one or a few PA infections will be included; the
CF-patients will be in the study until they get a new infection of PA or at the
longest for 2 years. Observation of the patients during the test period will closely
follow recommendations by ECFS. CF-E will observe that participating patients will
be treated in accordance to good clinical praxis. European Clinical Infrastructure
Network (Ecrin), will monitor the clinical study. Copenhagen will also do tests on
the mode of action of Anti-PA IgY and Vilnius, Lithuania will study if Anti-PA
IgY has any affect on the intestinal ﬂora.
93* Aspergillus bronchitis and ABPA in CF, a spectrum of disease
responding to antifungal therapy
N. Verma1, D.A. Spencer1, C. O’Brien1. 1Great North Children’s Hospital,
Department of Respiratory Paediatrics, Newcastle upon Tyne, United Kingdom
Background: Aspergillus is now the commonest organism cultured on bronchoalve-
olar lavage in symptomatic patients at our CF centre. Some symptomatic patients
with Aspergillus bronchitis have variable elevation of total IgE levels without
complete classical features of allergic bronchopulmonary aspergillosis (ABPA).
Classical ABPA is increasingly prevalent, affecting 12% of our patients but does
not always respond completely to steroid monotherapy. We are increasingly using
Voriconazole in both these patient groups.
Methods: Retrospective case note analysis including blood levels of all patients
who received Voriconazole between 2008–2010.
Results: 15 children aged between 5−15 years received Voriconazole for a mean
6 weeks. Voriconazole monotherapy was used in 8 children and in conjunction
with oral Prednisolone in the remainder. On Voriconazole alone, 7 had complete
resolution of symptoms, mean FEV1 increased from 1.47 to 1.75 (0–0.85 litres)
and mean IgE fell from 485 to 271 (0–500). On Voriconazole and Prednisolone,
5 had complete resolution of symptoms, mean FEV1 increased from 1.50 to 1.85
(0.1–1.05 litres) and mean IgE fell from 1050 to 710 (155–910). Side effects were
seen in 13 children (86%) with photosensitivity seen in 12. Sub-therapeutic levels
requiring an increase in dose were seen in 6 (40%) patients.
Conclusions: There is a role for antifungal therapy in both Aspergillus bronchitis
and in association with oral corticosteroids in patients with a major allergic
component. Dose adjustment is frequently required. Oral Voriconazole is expensive
and associated with signiﬁcant toxicity, alternative therapeutic strategies are still
required.
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Background: P. aeruginosa (PA) regulates virulence and bioﬁlm production using
QS − cell density-dependent signalling consisting of three key pathways − Las, Rhl
and Pqs. QS is a candidate therapeutic target for the treatment of PA lung infection
in CF.
Aim: To characterise the effect of a commercial garlic preparation upon QS-
regulated virulence of PA.
Method: QS-regulated virulence was evaluated in PAO1 and 2 clinical strains
(1 Liverpool epidemic, 1 sporadic) in the presence of garlic. Expression of QS
genes were assessed using lux-based chromosomal transcriptional fusions. Cognate
signal molecules were quantiﬁed by LCMS. Virulence factors in supernatants were
quantiﬁed using standard methods. Bioﬁlm growth on steel coupons was imaged
with an inverted confocal microscope and analysed using COMSTAT.
Results: Garlic reduced expression of QS genes and production of virulence factors
in all strains (data given for % reduction in PAO1). Signiﬁcant reductions (p< 0.01)
were observed in expression of the transcriptional regulators lasR (46%), rhlR (50%)
and pqsR (47%); signal synthase genes lasI (75%) and pqsA (99.7%); and virulence
genes lasB (82%), rhlA (82%) and lecA (30%). Garlic reduced production of PQS
and increased production of 3-oxo-C12 HSL signal molecules. The garlic group
showed reduced pyoverdin (51%), pyocyanin (90%) and elastase (66%), bacterial
attachment (43%) and bioﬁlm growth (88%) (p< 0.01).
Conclusion: A commercial garlic preparation exerts a pleotropic effect upon QS-
mediated gene expression and virulence factor production in PA. Quorum sensing
inhibitors, in particular garlic, may yield antibiotic adjuvant treatments for patients
with CF.
